Condition: Cancer Colorectal · Sponsor: Singlera Genomics Inc.
In this study, the investigators aimed to apply their previously developed multi-locus blood-based assay targeting circulating tumor DNA methylation to monitor postoperative relapse and evaluate adjuvant chemotherapy efficacy in resected stage I and stage II (without high risk) colorectal cancer after radical resection.
This description comes directly from the study's public registry record.
HongFeng cao, Ph.D · 13957117804 · hongfengcao@zju.edu.cn
Rui Liu, Ph.D · rliu@singleragenomics.com
Always discuss trial participation with your own doctor first.
| Second Affiliated Hospital | Hangzhou, Zhejiang, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05536089